CA2113614A1 - Methodes et compositions pour le traitement antimicrobien - Google Patents

Methodes et compositions pour le traitement antimicrobien

Info

Publication number
CA2113614A1
CA2113614A1 CA002113614A CA2113614A CA2113614A1 CA 2113614 A1 CA2113614 A1 CA 2113614A1 CA 002113614 A CA002113614 A CA 002113614A CA 2113614 A CA2113614 A CA 2113614A CA 2113614 A1 CA2113614 A1 CA 2113614A1
Authority
CA
Canada
Prior art keywords
bismuth subsalicylate
antimicrobial
treatment
safe
infection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002113614A
Other languages
English (en)
Inventor
Scott Donald Whalen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Procter and Gamble Co
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2113614A1 publication Critical patent/CA2113614A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA002113614A 1991-07-24 1992-07-15 Methodes et compositions pour le traitement antimicrobien Abandoned CA2113614A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73540091A 1991-07-24 1991-07-24
US735,400 1991-07-24

Publications (1)

Publication Number Publication Date
CA2113614A1 true CA2113614A1 (fr) 1993-02-04

Family

ID=24955626

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002113614A Abandoned CA2113614A1 (fr) 1991-07-24 1992-07-15 Methodes et compositions pour le traitement antimicrobien

Country Status (10)

Country Link
EP (1) EP0595890A1 (fr)
JP (1) JPH06509340A (fr)
AU (1) AU2324392A (fr)
BR (1) BR9206300A (fr)
CA (1) CA2113614A1 (fr)
IE (1) IE922403A1 (fr)
MA (1) MA22597A1 (fr)
MX (1) MX9204338A (fr)
PT (1) PT100729A (fr)
WO (1) WO1993001818A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPN771596A0 (en) 1996-01-25 1996-02-15 Mclean, Allan Joseph Methods of and compositions for potentiating the action of agents active on cell-wall sites of susceptible bacteria
DE10236347A1 (de) † 2002-08-08 2004-02-19 Basf Coatings Ag Wäßrige Elektrotauchlacke, ihre Verwendung in Verfahren zur Beschichtung elektrisch leitfähiger Substrate sowie die Verwendung von Bismutverbindungen in diesen wäßrigen Elektrotauchlacken
WO2005014567A1 (fr) * 2003-08-12 2005-02-17 Biocon Limited Sel de bismuth a acide mycophenolique
CA3018872A1 (fr) * 2016-03-24 2017-09-28 Paratek Pharmaceuticals, Inc. Methodes de traitement et de prevention d'une infection a

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE135582T1 (de) * 1985-06-13 1996-04-15 Barry James Marshall Verfahren und zusammensetzungen zur behandlung von gastrointestinalen störungen
JP2733849B2 (ja) * 1987-10-12 1998-03-30 ボロディー，ソーマス・ユリウス 胃腸障害治療のための改良された方法

Also Published As

Publication number Publication date
MX9204338A (es) 1993-03-01
MA22597A1 (fr) 1993-04-01
PT100729A (pt) 1993-10-29
AU2324392A (en) 1993-02-23
IE922403A1 (en) 1993-01-27
JPH06509340A (ja) 1994-10-20
WO1993001818A1 (fr) 1993-02-04
EP0595890A1 (fr) 1994-05-11
BR9206300A (pt) 1994-08-02

Similar Documents

Publication Publication Date Title
Marshall Treatment strategies for Helicobacter pylori infection
EP0616808B1 (fr) Emploi de la rifaximine et de ses compositions pharmaceutiques dans le traitement de la dyspepsie gastrique causée par l'helicobacter pylori
JP5469511B2 (ja) 微生物の院内感染症の治療用医薬の製造におけるタウロリジンまたはタウラルタムのような抗微生物薬剤の使用
JPH0794390B2 (ja) 胃腸疾患の治療のための医薬組成物
RO115780B1 (ro) Combinatie sinergica
KR19990022220A (ko) 의료 용도의 미소-캡슐화된 락토바실러스
RU2116071C1 (ru) Лекарственные препараты, набор и способ лечения желудочно-кишечных заболеваний, вызываемых или опосредуемых заражением helicobaeter pylori
CN106620649A (zh) 使用单剂量奥利万星的治疗方法
Cunha Nitrofurantoin—current concepts
JP2002500189A5 (fr)
DE69125940T2 (de) Pharmazeutische zusammensetzungen die 5-difluormethoxy-2-[3,4-dimethoxy-2-pyridyl)methylsulfinyl]-1h-benzimidazol und ein anti-heliobactermittel enthalten zur behandlung von magen-darm krankheiten
Ristuccia et al. Current concepts in antimicrobial therapy of prostatitis
CA2113614A1 (fr) Methodes et compositions pour le traitement antimicrobien
Graninger et al. Quinolones in gastrointestinal infections.
Fabian et al. Antibiotics in penetrating abdominal trauma: comparison of ticarcillin plus clavulanic acid with gentamicin plus clindamycin
WO2016081825A1 (fr) Procédés et compositions pour le traitement de maladie associée au clostridium difficile
US3949077A (en) Synergistic antibiotic compositions
Sartori et al. Acute gastroduodenal mucosal injury after cisplatin plus etoposide chemotherapy: clinical and endoscopic study
KR20010024050A (ko) 항균제
EP0591446B1 (fr) Procede de traitement des gastrites a helicobacter pylori
Glupczynski In vitro susceptibility of Helicobacter pylori to antibiotics and bismuth salts and the importance of acquired resistance to antibiotics in treatment failures of H. pylori infection
Pimentel et al. Efficacy and safety of norfloxacin 800 mg once-daily versus norfloxacin 400 mg twice-daily in the treatment of uncomplicated urinary tract infections in women: a double-blind, randomized clinical trial
NAKAYA et al. Antimicrobial agents and intestinal microflora
Slack et al. The microbiological and pharmacokinetic profile of an antibacterial agent useful for the single-dose therapy of urinary tract infection
Sharma et al. Cefuroxime Axetil: An oral prodrug of cefuroxime sodium

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead